Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Mise à jour : Il y a 4 ans
Référence : NCT00413283

Femme et Homme

Extrait

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.


Critère d'inclusion

  • Lung cancer ,chemotherapy induced thrombocytopenia ,non-small cell lung cancer ,Cancer ,Lung Neoplasms ,Oncology ,Solid Tumors ,Thrombocytopenia


Liens